China SXT Pharmaceuticals
SXTC
0 hedge funds and large institutions have $279K invested in China SXT Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
64% less capital invested
Capital invested by funds: $769K → $279K (-$490K)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$546K |
| 2 |
HF
HRT Financial
New York
|
-$80K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$14K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$11K |
| 5 |
VF
Virtu Financial
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Renaissance Technologies
New York
| $218K | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $35K | – | – | – |
|
3
UBS Group
Zurich,
Switzerland
| $18K | – | – | – |
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $6K | – | – | – |
|
|
HI
5
Hudock Inc
Williamsport,
Pennsylvania
| $2K | – | – | – |
|
|
6
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$546K | -1 | Closed |
|
|
7
Acadian Asset Management
Boston,
Massachusetts
| – | -$14K | – | – |
|
|
BWA
8
Beam Wealth Advisors
Covington,
Louisiana
| – | -$4K | – | – |
|
|
ECM
9
ExodusPoint Capital Management
New York
| – | -$11K | – | – |
|
|
HF
10
HRT Financial
New York
| – | -$80K | – | – |
|
|
VF
11
Virtu Financial
New York
| – | -$5K | – | – |
|
SXTC Hedge Fund Activity: Q4 2020 in Review
0 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q4 2020, worth a combined $279K — down 64% from $769K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SXTC and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $546K sold.
- 0 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q4 2020, down from 1 in Q3 2020.
- Funds reported $279K of China SXT Pharmaceuticals stock for Q4 2020, down 64% quarter-over-quarter.
- 0 funds opened new China SXT Pharmaceuticals positions in Q4 2020 and 1 closed out, a net change of -1 holder.
- The largest China SXT Pharmaceuticals seller in Q4 2020 was Hudson Bay Capital Management, an estimated $546K sold.
Based on aggregated 13F filings for Q4 2020.